[SCHEDULE 13G/A] Mineralys Therapeutics, Inc. SEC Filing
Mineralys Therapeutics (MLYS) Schedule 13G/A reports that BioDiscovery 6 FPCI, Andera Partners and two Andera managing partners, Stephane Bergez and Francois Xavier Mauron, together may be deemed to beneficially own 2,765,976 shares of common stock, representing 4.2% of the class based on 65,175,287 shares outstanding as of May 8, 2025. The shares are held of record by BioDiscovery 6; voting and dispositive authority is shared (no sole voting or dispositive power reported). The filers disclaim status as a group. The filing discloses Paris as the reporting persons' principal address and includes a joint filing agreement as an exhibit.
Mineralys Therapeutics (MLYS) 鈥� nel modulo Schedule 13G/A si segnala che BioDiscovery 6 FPCI, Andera Partners e due partner di gestione di Andera, St茅phane Bergez e Fran莽ois Xavier Mauron, potrebbero essere considerati titolari benefici di 2.765.976 azioni ordinarie, pari al 4,2% della categoria su un totale di 65.175.287 azioni in circolazione al 8 maggio 2025. Le azioni risultano registrate a nome di BioDiscovery 6; l'autorit脿 di voto e dispositiva 猫 condivisa (non 猫 indicato alcun potere di voto o dispositivo esclusivo). I firmatari rinunciano allo status di gruppo. L'indirizzo principale dei reporting person 猫 dichiarato a Parigi e il deposito include un accordo di presentazione congiunta come allegato.
Mineralys Therapeutics (MLYS) 鈥� en el Schedule 13G/A se informa que BioDiscovery 6 FPCI, Andera Partners y dos socios gestores de Andera, St茅phane Bergez y Fran莽ois Xavier Mauron, pueden considerarse titulares beneficiarios de 2.765.976 acciones ordinarias, lo que representa el 4,2% de la clase sobre 65.175.287 acciones en circulaci贸n a fecha de 8 de mayo de 2025. Las acciones est谩n registradas a nombre de BioDiscovery 6; la autoridad de voto y dispositiva se comparte (no se declara poder exclusivo de voto ni dispositivo). Los declarante renuncian a la condici贸n de grupo. La presentaci贸n indica Par铆s como la direcci贸n principal de las personas informantes e incluye un acuerdo de presentaci贸n conjunta como anexo.
Mineralys Therapeutics (MLYS)鞚� Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� BioDiscovery 6 FPCI, Andera Partners 氚� Andera鞚� 霊� 鞖挫毄 韺岉姼雱堨澑 St茅phane Bergez鞕� Fran莽ois Xavier Mauron臧� 頃╈硱靹� 2,765,976欤�鞚� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚措姅 2025雲� 5鞗� 8鞚� 旮办 氚滍枆欤检嫕 65,175,287欤� 欷� 4.2%鞐� 頃措嫻頃╇媹雼�. 欤检嫕鞚� 氇呾潣靸� BioDiscovery 6鞐� 氤挫湢霅橃柎 鞛堨溂氅�, 鞚橁舶甓� 氚� 觳橂秳甓岇潃 瓿奠湢(雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓)頃╇媹雼�. 鞁犼碃鞚鸽摛鞚� 攴鸽９ 歆�鞙勲ゼ 攵�鞚疙暕雼堧嫟. 氤搓碃靹滌棎電� 氤搓碃鞚胳潣 欤检殧 欤检唽臧� 韺岆Μ搿� 旮办灛霅橃柎 鞛堨溂氅�, 瓿惦彊 鞝滌稖 瓿勳暯靹滊ゼ 歃濍箼靹滊搿� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Mineralys Therapeutics (MLYS) 鈥� le Schedule 13G/A indique que BioDiscovery 6 FPCI, Andera Partners et deux associ茅s gestionnaires d'Andera, St茅phane Bergez et Fran莽ois Xavier Mauron, peuvent 锚tre r茅put茅s d茅tenir b茅n茅volement 2 765 976 actions ordinaires, soit 4,2 % de la cat茅gorie sur 65 175 287 actions en circulation au 8 mai 2025. Les actions sont inscrites au registre au nom de BioDiscovery 6 ; l'autorit茅 de vote et de disposition est partag茅e (aucun pouvoir exclusif de vote ou de disposition d茅clar茅). Les d茅posants d茅clinent le statut de groupe. Le dossier indique Paris comme adresse principale des personnes d茅clarantes et comprend un accord de d茅p么t conjoint en annexe.
Mineralys Therapeutics (MLYS) 鈥� im Schedule 13G/A wird berichtet, dass BioDiscovery 6 FPCI, Andera Partners und zwei gesch盲ftsf眉hrende Partner von Andera, St茅phane Bergez und Fran莽ois Xavier Mauron, zusammen als wirtschaftliche Eigent眉mer von 2.765.976 Aktien der Stammaktien angesehen werden k枚nnten, was 4,2% der Klasse von insgesamt 65.175.287 ausgegebenen Aktien per 8. Mai 2025 entspricht. Die Aktien sind auf BioDiscovery 6 eingetragen; Stimm- und Verf眉gungsbefugnisse werden geteilt (keine alleinige Stimm- oder Verf眉gungsgewalt angegeben). Die Einreicher bestreiten den Status als Gruppe. Als Hauptadresse der meldepflichtigen Personen wird Paris angegeben und eine gemeinsame Einreichungsvereinbarung ist als Anlage beigef眉gt.
- None.
- None.
Insights
TL;DR: A non-U.S. investor group reports a sub-5% passive stake (4.2%) in Mineralys with shared voting/dispositive power.
The Schedule 13G/A shows a passive ownership position below the 5% threshold, which generally indicates non-control intent under SEC reporting categories. The economic exposure of 2,765,976 shares is disclosed with shared voting and dispositive authority, implying control of record shares rests with BioDiscovery 6 while Andera's management participates in decisions. Given the 4.2% stake, this disclosure is informational and unlikely to trigger material changes in governance or financing dynamics absent subsequent increases in position or coordination.
TL;DR: Reporting parties disclose shared authority but disclaim a formal group; no evidence of change-in-control intent.
The filing's certification states the securities were not acquired to influence control, consistent with Schedule 13G treatment. Shared voting and dispositive power via the management company is clearly noted, and the explicit disclaimer of group status reduces immediate governance concerns. Investors should view this as enhanced transparency about ownership structure rather than an activist or control-driven disclosure.
Mineralys Therapeutics (MLYS) 鈥� nel modulo Schedule 13G/A si segnala che BioDiscovery 6 FPCI, Andera Partners e due partner di gestione di Andera, St茅phane Bergez e Fran莽ois Xavier Mauron, potrebbero essere considerati titolari benefici di 2.765.976 azioni ordinarie, pari al 4,2% della categoria su un totale di 65.175.287 azioni in circolazione al 8 maggio 2025. Le azioni risultano registrate a nome di BioDiscovery 6; l'autorit脿 di voto e dispositiva 猫 condivisa (non 猫 indicato alcun potere di voto o dispositivo esclusivo). I firmatari rinunciano allo status di gruppo. L'indirizzo principale dei reporting person 猫 dichiarato a Parigi e il deposito include un accordo di presentazione congiunta come allegato.
Mineralys Therapeutics (MLYS) 鈥� en el Schedule 13G/A se informa que BioDiscovery 6 FPCI, Andera Partners y dos socios gestores de Andera, St茅phane Bergez y Fran莽ois Xavier Mauron, pueden considerarse titulares beneficiarios de 2.765.976 acciones ordinarias, lo que representa el 4,2% de la clase sobre 65.175.287 acciones en circulaci贸n a fecha de 8 de mayo de 2025. Las acciones est谩n registradas a nombre de BioDiscovery 6; la autoridad de voto y dispositiva se comparte (no se declara poder exclusivo de voto ni dispositivo). Los declarante renuncian a la condici贸n de grupo. La presentaci贸n indica Par铆s como la direcci贸n principal de las personas informantes e incluye un acuerdo de presentaci贸n conjunta como anexo.
Mineralys Therapeutics (MLYS)鞚� Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� BioDiscovery 6 FPCI, Andera Partners 氚� Andera鞚� 霊� 鞖挫毄 韺岉姼雱堨澑 St茅phane Bergez鞕� Fran莽ois Xavier Mauron臧� 頃╈硱靹� 2,765,976欤�鞚� 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚措姅 2025雲� 5鞗� 8鞚� 旮办 氚滍枆欤检嫕 65,175,287欤� 欷� 4.2%鞐� 頃措嫻頃╇媹雼�. 欤检嫕鞚� 氇呾潣靸� BioDiscovery 6鞐� 氤挫湢霅橃柎 鞛堨溂氅�, 鞚橁舶甓� 氚� 觳橂秳甓岇潃 瓿奠湢(雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 鞐嗢潓)頃╇媹雼�. 鞁犼碃鞚鸽摛鞚� 攴鸽９ 歆�鞙勲ゼ 攵�鞚疙暕雼堧嫟. 氤搓碃靹滌棎電� 氤搓碃鞚胳潣 欤检殧 欤检唽臧� 韺岆Μ搿� 旮办灛霅橃柎 鞛堨溂氅�, 瓿惦彊 鞝滌稖 瓿勳暯靹滊ゼ 歃濍箼靹滊搿� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Mineralys Therapeutics (MLYS) 鈥� le Schedule 13G/A indique que BioDiscovery 6 FPCI, Andera Partners et deux associ茅s gestionnaires d'Andera, St茅phane Bergez et Fran莽ois Xavier Mauron, peuvent 锚tre r茅put茅s d茅tenir b茅n茅volement 2 765 976 actions ordinaires, soit 4,2 % de la cat茅gorie sur 65 175 287 actions en circulation au 8 mai 2025. Les actions sont inscrites au registre au nom de BioDiscovery 6 ; l'autorit茅 de vote et de disposition est partag茅e (aucun pouvoir exclusif de vote ou de disposition d茅clar茅). Les d茅posants d茅clinent le statut de groupe. Le dossier indique Paris comme adresse principale des personnes d茅clarantes et comprend un accord de d茅p么t conjoint en annexe.
Mineralys Therapeutics (MLYS) 鈥� im Schedule 13G/A wird berichtet, dass BioDiscovery 6 FPCI, Andera Partners und zwei gesch盲ftsf眉hrende Partner von Andera, St茅phane Bergez und Fran莽ois Xavier Mauron, zusammen als wirtschaftliche Eigent眉mer von 2.765.976 Aktien der Stammaktien angesehen werden k枚nnten, was 4,2% der Klasse von insgesamt 65.175.287 ausgegebenen Aktien per 8. Mai 2025 entspricht. Die Aktien sind auf BioDiscovery 6 eingetragen; Stimm- und Verf眉gungsbefugnisse werden geteilt (keine alleinige Stimm- oder Verf眉gungsgewalt angegeben). Die Einreicher bestreiten den Status als Gruppe. Als Hauptadresse der meldepflichtigen Personen wird Paris angegeben und eine gemeinsame Einreichungsvereinbarung ist als Anlage beigef眉gt.
FAQ
What stake in Mineralys Therapeutics (MLYS) is reported in this Schedule 13G/A?
Who are the reporting persons on this filing for MLYS?
Do the filers claim they form a group or intend to influence control of MLYS?
What voting and dispositive powers are disclosed by the filers?
Where is the reporting party located and is there an exhibit attached?
